207_Combined course Presentations
Future Perspectives…
PACIFIC PD-L1 Phase III Trial Consolidative therapy with Durvalumab vs Placebo
Placebo
Chemoradiotherapy
MEDI 4736 – Durvalumab (PD-L1 inhibitor)
Planned accrual: 702 pts, >100 sites Endpoints: PFS, OS
Made with FlippingBook